mutated lung cancer

Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer

Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer

Phase 1 Study Supports Recommended Phase 3 Dose for Investigational EGFR x HER3 Antibody-Drug Conjugate in EGFR-Mutated Lung Cancer

Investigational KRAS(ON) inhibitor zoldonrasib showed effective and durable responses in patients with advanced G12D-mutated lung cancer - EurekAlert!

University of Cincinnati Cancer Center targets key enzyme complex to treat KRAS-mutated lung cancer - EurekAlert!